Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from the integrated safety analysis of filgotinib in patients with RA.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderately to Severely Active RA.‘ (Abstract number: 0273) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What has been the impact of filgotinib on the treatment of patients with RA and what challenges are associated with its use? (0:15)
- What were the objectives and methodology of your analysis? (0:58)
- What were the findings in terms of incidence of adverse events with filgotinib in this analysis? (1:55)
- What were the differences in adverse events of special interest among different filgotinib dosage groups? (2:40)
- What were the key take home messages of the study? (3:52)
Disclosures: Kevin Winthrop discloses consulting for Pfizer, AbbVie, Union Chimique Belge (UCB), Eli Lilly & Company, Galapagos, GlaxoSmithKline (GSK), Roche, Gilead, BMS, Regeneron, Sanofi, AstraZeneca, and Novartis; and receiving grant/ research support from BMS and Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
